Alexion Pharmaceuticals (ALXN) Receives a Buy from Credit Suisse

Credit Suisse analyst Martin Auster maintained a Buy rating on Alexion Pharmaceuticals (ALXN – Research Report) yesterday and set a price target of $156. The company’s shares closed yesterday at $118.52. According More »

The EC of Five Prime Therapeutics is Exercising Options

Yesterday it was reported that the EC of Five Prime Therapeutics (FPRX – Research Report), Lewis Williams, exercised options to buy 91,217 FPRX shares at $4.56 a share, for a total transaction More »